PCOS Weekly Literature Review

Jul 29, 2026

∙ Paid

PROVATION LIFE | Women’s Health Intelligence PAID MEMBERS ONLY

Executive Summary

ESG formally endorses renaming PCOS to “polyendocrine metabolic ovary syndrome (PMOS),” backed by a 56-organization consensus — opinion-driven, zero new clinical data, but real downstream implications for patient materials and coding. (PMID 42367168)
The most rigorous PCOS-drug synthesis this week: liraglutide has the deepest PCOS-specific evidence among incretins; semaglutide’s evidence is thin but promising; tirzepatide has zero PCOS-specific data — any use today is extrapolation, full stop. (PMID 42106472)
A companion commentary flags an unresolved safety gap: GLP-1 use in PCOS adolescents has no reproductive-outcome data and a theoretical, unproven bone-density risk during peak bone-mass years. (PMID 42364709)
Two diet papers converge on modest, actionable guidance: a 6-week RCT favors early time-restricted eating (8am–6pm) over mid-day TRE for lipids; a 38-study systematic review confirms diet broadly helps weight/insulin but not consistently lipids or inflammation. (PMID 42371138, 42371137)
A small, retrospective, supplement-industry-adjacent pilot claims a specific 3.6:1 myo-inositol:D-chiro-inositol ratio improves IVF outcomes in PCOS — promising direction, weak design, not yet practice-changing. (PMID 42334964)